Biosimilar Watch: FDA Accepts BLA for Proposed Stelara Biosimilar
The Dermatology Digest
JANUARY 4, 2024
The clinical results demonstrated that DMB-3115 and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of quality, safety and efficacy. market during the next five years. Accord BioPharma is planning to introduce several additional biosimilars to the U.S.
Let's personalize your content